Several investigators have suggested that long-term treatment with nitrates in patients with angina pectoris is associated with the development of tolerance. Although this theory is in contrast to the clinical experience of most cardiologists, it is supported by evidence from controlled trials, reported by Parker, Rudolph, Thadani and their coworkers. In this chapter the subject is reviewed, with the conclusion that tolerance to the antianginal effect can be reduced if the drugs are appropriately used. The topic is subdivided into three main areas:
Tolerance to the antianginal effect
KeywordsAngina Pectoris Guanylate Cyclase Isosorbide Dinitrate Organic Nitrate Chronic Therapy
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Unable to display preview. Download preview PDF.
- 5.Bennett D, Barclay SA, Adam J, Valentine H, Boyle GJ (1987) Transdermal nitroglycerin causes plasma volume expansion which may explain tolerance to transdermal nitroglycerin. Eur Heart J 8[Suppl 1]: 18Google Scholar
- 7.Distante A, Lombardi M, Morales MA, Moscarelli E, L’Abbate A (1985) Preserved hemodynamic response to acute dose of ISDN in anginal patients chronically treated with the same drug percutaneously (Abstract). Eur Heart J 5[Suppl 1]: 269Google Scholar
- 13.Nyberg G, Nilsson B (1985) Antianginal efficacy of isosorbide-5-mononitrate in a controlled-release (durules) formulation. Br J Clin Pharmacol 20: 504PGoogle Scholar
- 15.Rennhak U, Riebesel T, Biamino G (1985) A double-blind cross-over study on the effectiveness and possible development of tolerance during long-term therapy with isosorbide-5-mononitrate or isosorbide dinitrate slow-release in coronary artery disease. In: Cohn JN, Rittinghausen R (eds) Mononitrates. Springer, Berlin Heidelberg New York, pp 147–153CrossRefGoogle Scholar
- 21.Silber S, Krause KH, Garner G, Theisen K, Jahrmarker H (1983) Anti-ischemic effects of an 80 mg tablet of isosorbide dinitrate in sustained-release form before and after 2 weeks of treatment with 80 mg once daily or twice daily. K Kardiol 72[Suppl 3]: 211–217Google Scholar
- 22.Boertz A, Bonn R (1986) Nitrates therapy without loss of action by correct dosage. Z Kardiol 7[Suppl 3]: 57–69Google Scholar
© Springer-Verlag Berlin Heidelberg 1990